 PERTH, Australia--BUSINESS WIRE--- OCC ASX--Australian-based regenerative medicine company, Orthocell Ltd ASX:OCC, Orthocell or the Company, has achieved US 510k clearance to market and supply its collagen medical device StriateTM in the US dental bone and tissue regeneration market. Orthocell Managing Director, Paul Anderson, said: US approval is a significant inflection point for our Company, and we are now primed to partner and distribute this product. I look forward to working with our leadi 